Polymorphs of Compound A Mesylate for Cancer Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatments, particularly for metastatic disease, lack effective drugs for long-term cure and are challenged by the heterogeneity of cancer cells, making it difficult to predict response to chemotherapeutic agents, and there is a need for new compounds that can modulate AKT genes to treat proliferation disorders effectively.
Innovation Solution
Development of a polymorph of a mesylate salt of Compound A, specifically in forms such as Form A, Form B, and others, which exhibit specific X-ray powder diffraction peaks, and their use in pharmaceutical compositions to treat or prevent cell proliferative disorders, along with methods for preparing these stable solid state forms.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple mutational mechanisms lead to cancer heterogeneity, then cancer cell diversity increases, but predictability of chemotherapeutic response decreases
Solution Approach 1:
The patent employs parameter changes by developing multiple chemotherapeutic agents with different molecular structures and mechanisms of action (e.g., compounds targeting AKT pathway with varying potencies and selectivities). This allows clinicians to select appropriate drugs based on specific cancer characteristics, thereby addressing the heterogeneity challenge while maintaining predictable response through personalized parameter matching.
Solution Approach 2:
The patent segments the cancer treatment approach by identifying and targeting specific mutational mechanisms and signaling pathways (such as AKT1, AKT2, AKT3 isoforms) separately. This segmentation enables the development of targeted therapies that can predictably respond to specific cancer subtypes, overcoming the overall heterogeneity problem by treating specific segments of the disease.
2Adaptability or versatility
If receptor tyrosine kinases are dysregulated by mutation and amplification, then cellular signaling becomes abnormal, but controlled cellular growth becomes uncontrolled
Solution Approach 1:
The patent applies parameter changes by developing small molecule inhibitors that specifically bind to and modulate the activity of dysregulated receptor tyrosine kinases and downstream AKT pathway components. These compounds restore normal signaling parameters by reducing abnormal phosphorylation levels and protein activation, thereby re-establishing controlled cellular growth despite the presence of mutations and amplifications.
Solution Approach 2:
The patent converts the harmful effect of dysregulated signaling into a benefit by using the abnormal signaling activity itself as a target. The inhibitors are designed to specifically recognize and bind to the altered conformational states of mutated kinases, thereby converting the pathological signaling into a detectable and treatable target that can be selectively inhibited to restore growth control.
3Reliability
If Akt1 blocks apoptosis to promote cell survival, then cancer cell survival increases, but treatment efficacy decreases
Solution Approach 1:
The patent converts the harmful apoptotic blockade into a benefit by using the survival-promoting AKT pathway as a therapeutic target. The inhibitors specifically block AKT-mediated anti-apoptotic signaling, thereby converting the cancer cell's survival advantage into a vulnerability that can be exploited for treatment. This approach transforms the reliability of cell survival into a predictable treatment efficacy by reversing the survival mechanism.
Solution Approach 2:
The patent applies parameter changes by modulating the activity of AKT pathway components to shift the balance from survival promotion to apoptotic activation. The inhibitors reduce phosphorylation levels of downstream substrates and decrease protein stability, thereby changing the cellular parameter from high survival to induced apoptosis, which improves treatment efficacy while maintaining reliability through targeted action.
4Adaptability or versatility
If new chemotherapies are developed for resistant tumors, then treatment options increase, but the need for new drugs continues
Solution Approach 1:
The patent applies preliminary action by developing combination therapies that use multiple agents with different mechanisms of action simultaneously or in sequence. This preliminary multi-pronged approach prevents the development of resistance by targeting multiple pathways at once, thereby extending the efficacy of existing treatments and reducing the frequency with which entirely new drugs must be developed, thus addressing the continuous need for new chemotherapies.
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present application relates to salts of Compound A, 3-(3-(4-(1-aminocyclobutyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine, solid state forms of Compound A free base or of salts of Compound A, amorphous forms of Compound A free base or of salts of Compound A, crystalline forms of Compound A free base or of salts of Compound A, polymorphs of Compound A free base or of salts of Compound A, and mesomorphs of Compound A free base or of salts of Compound A. The present application also relates to pharmaceutical compositions comprising these salts, solid state forms, amorphous forms, crystalline forms, polymorphs, or mesomorphs of Compound A free base or of salts of Compound A. The present application provides methods for preparing these salts, solid state forms, amorphous forms, crystalline forms, polymorphs, or mesomorphs of Compound A free base or of salts of Compound A.